title: TRAIL pathway components and their putative role in granulosa cell apoptosis in the human ovary.
abstract: Extensive apoptotic oocyte reduction occurs during fetal ovarian development. The regulatory pathways responsible for oocyte selection to programmed cell death are, however, poorly understood. The aim of this study was to investigate the potential involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its death receptors TRAIL-R1/DR4 and TRAIL-R2/DR5 and decoy receptors TRAIL-R3/DcR1 and TRAIL-R4/DcR2 in the apoptotic process characterizing human fetal and adult ovaries. For this purpose, in situ hybridization and immunohistochemistry were applied to human fetal and adult ovarian samples to study the mRNA and protein expression of TRAIL pathway components, and a human granulosa cell tumor-derived cell line (KGN) was used to elucidate functional effects of TRAIL on apoptosis. TRAIL was expressed in human fetal ovary from the 11th week until term. The pro-apoptotic TRAIL-R2/DR5 and the anti-apoptotic TRAIL-R4/DcR2 were also expressed in human ovaries throughout the fetal period. Among the different ovarian cell types, these TRAIL pathway components were mainly localized in the oocytes, and their expression increased towards term. Expression of TRAIL-R1/DR4 and TRAIL-R3/DcR1 was negligible in all of the fetal ovaries studied. Adult ovaries expressed TRAIL, TRAIL-R2/DR5, TRAIL-R3/DcR1 and TRAIL-R4/DcR2 in granulosa cells and oocytes of small primary/secondary follicles as well as in granulosa and theca cells of more developed antral follicles. In KGN cells, TRAIL efficiently induced apoptosis in a dose-dependent manner, and this was blocked by a caspase inhibitor. The results indicate a role of the TRAIL pathway components in the regulation of granulosa cell apoptosis in in vitro and suggest that these factors may have a role in regulating ovarian apoptosis also in vivo.
authors.affiliation: Department of Obstetrics and Gynecology, University of Oulu, P.O. Box 5000, FIN-90014, Oulu, Finland.
authors.forename: M
authors.initials: M
authors.lastname: Jääskeläinen
authors.forename: A
authors.initials: A
authors.lastname: Kyrönlahti
authors.forename: M
authors.initials: M
authors.lastname: Anttonen
authors.forename: Y
authors.initials: Y
authors.lastname: Nishi
authors.forename: T
authors.initials: T
authors.lastname: Yanase
authors.forename: P
authors.initials: P
authors.lastname: Secchiero
authors.forename: G
authors.initials: G
authors.lastname: Zauli
authors.forename: J S
authors.initials: JS
authors.lastname: Tapanainen
authors.forename: M
authors.initials: M
authors.lastname: Heikinheimo
authors.forename: T E
authors.initials: TE
authors.lastname: Vaskivuo
mesh_terms: D017209:Apoptosis; D005260:Female; D005333:Fetus / Q000166:cytology / Q000502:physiology; D005786:Gene Expression Regulation; D006107:Granulosa Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D010053:Ovary / Q000166:cytology* / Q000502:physiology*; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology*
chemical_list: D053221:TNF-Related Apoptosis-Inducing Ligand